Open AccessLong-term survival in a patient with metastatic HER2+ breast cancer undergoing lapatinib-based therapy for 6 years
Author(s) -
Salvatore Tumolo,
S. Conforti
Publication year - 2018
Publication title -
aboutopen
Language(s) - English
Resource type - Journals
ISSN - 2465-2628
DOI - 10.19156/abtpn.2018.0032
Subject(s) - lapatinib , capecitabine , medicine , trastuzumab , breast cancer , oncology , metastatic breast cancer , chemotherapy , cancer , adjuvant therapy , colorectal cancer
We report the case of a patient with HER2-positive breast cancer under adjuvant therapy (chemotherapy and trastuzumab) who developed a recurrence with bone (cervical spine) and lung involvement. After treatment with lapatinib and capecitabine, the patient remained stable with considerable improvement of her physical condition. After 6 years she is still in maintenance therapy with lapatinib. This case is among a number of long term surviving and long term responding patients, within an atypical subset of patients with HER2-positive metastatic breast cancer, in the presence of encephalic lesions (Oncology).